Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. At this time, I would like to welcome everyone to Xenon Pharmaceutical's second quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. I will now turn the conference over to Chad Fugger. You may begin. Good afternoon. Thank you for joining us in our call and webcast to discuss Zinon's second quarter 2025 financial and operating results. Joining me are Ian Mortimer, Zinon's president and chief executive officer, Dr. Chris Kenney, Zinon's chief medical officer, and Darren Klein, Zinon's chief commercial officer. After completing their prepared remarks today, we will open the call up for your questions. Please be advised that during this call, we will make a number of statements that are forward looking. including statements regarding the timing of potential results from clinical trials, the potential efficacy, basic profile, future development plans, and current and anticipated indication, addressable market, regulatory success, and commercial potential of our and our partners' product candidates, the efficacy of our clinical trial designs, our ability to successfully develop and achieve milestones in our clinical development program, including the anticipated filing of INDs and NDAs, the timing and results of those filings, and our interactions with regulators, and our ability to successfully obtain regulatory approvals, anticipated timing of the top-line data readout for our clinical trials at the Zetu calendar, and our expectation that we will have sufficient cash to fund operations in the 202...